ucm05194

UCM-05194 is a selective LPA1 receptor agonist that can improve neuropathic pain and can be used in the study of progressive system diseases.

JS25 is a selective, covalent BTK inhibitor that deactivates BTK by chelating Tyr551, exhibiting an IC50 of 5.8 nM. It suppresses cancer cell proliferation, induces pronounced cell death, and enhances Burkitt's lymphoma murine xenograft model outcomes. Importantly, JS25 efficiently penetrates the blood-brain barrier.

UCM-05194 (ammonium) is an agonist for the lysophosphatidic acid receptor 1 (LPA1). It induces calcium mobilization in RH7777 cells expressing LPA1, with an EC50 of 0.24 µM. In B103 rat neuroblastoma cells that overexpress LPA1, UCM-05194 (ammonium) promotes neurite retraction and cell migration. Additionally, it alleviates acetic acid-induced writhing and mechanical hyperalgesia in mice.